[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557865":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":48,"collaborators":20,"id":52,"slug":20,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Iran University of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Limbal Stem Cell Derived Exosome Eye Drop treatment","EXPERIMENTAL","Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drop intervention for 3 months.",[13],"Biological: Limbal Stem Cell Derived Exosomes Eye Drop",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Limbal Stem Cell Derived Exosomes Eye Drop","Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drops 0.15 ml\u002Fsingle eye\u002Fone time, four times a day for 3 months. The follow-up visit will be 12 weeks since the administration of LSC-Exo eye drops.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Hossein Aghaei, MD","CONTACT","+982155661188","draghaei.h@gmail.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Alireza Shoae-Hassani","+989121454878","cell.therapy@yahoo.com",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":20,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Moheb Kowsar Hospital","RECRUITING","Tehran","Iran",{"type":38,"coordinates":39},"Point",[40,41],51.42151,35.69439,{"lat":41,"lon":40},[44],{"name":45,"role":24,"phone":46,"phoneExt":20,"email":47},"Kian Alirezaei, MD","+989034561467","Kian.alirezaei.72@gmail.com",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Alireza Shoae Hassani","Director","100557865",false,"NCT06543667","Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye","A Clinical Study for Safety and Efficacy Evaluation of Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye Syndrome","EXOIUMS","Inclusion Criteria:\n\n* Patients with complaints of burning or itching or feeling of a foreign body in the eye\n* Moderate and severe dry eye severity\n* Age between 18-70 years\n\nExclusion Criteria:\n\n* Previous history of eye surgery\n* Any disease that suppresses the immune system\n* Pregnancy and breastfeeding\n* Eyelid abnormalities\n* Use of eye drops in the past year except artificial tears and lubricating ointments\n* Use of systemic drugs that affect the tear film in last three months\n* Use of contact lenses in the last three months","ALL","18 Years","70 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67],"PHASE1","The purpose of this study is to determine the safety and efficacy of Limbal Stem Cells derived Exosomes (LSC-Exo) in alleviation of dry eye symptoms",[70],"Dry Eye Syndromes",[72,73,74],"Dry Eye Disease","Sjogren's Syndrome","Chronic Dry Eye","2025-04-30",{"date":77,"type":78},"2025-05-01","ACTUAL",{"date":80,"type":78},"2024-08-01",{"date":82,"type":64},"2026-07-01",{"name":5,"class":6},1]